Back to Search Start Over

The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapya combined analysis of two randomised, placebo-controlled phase III clinical trials

The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapya combined analysis of two randomised, placebo-controlled phase III clinical trials

Authors :
R DEWIT
J HERRSTEDT
B RAPOPORT
A CARIDES
J GUOGUANGMA
M ELMER
C SCHMIDT
J EVANS
K HORGAN
Source :
European Journal of Cancer. 40:403-410
Publication Year :
2004
Publisher :
Elsevier BV, 2004.

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
09598049
Volume :
40
Database :
OpenAIRE
Journal :
European Journal of Cancer
Accession number :
edsair.doi...........62145730b508834036535746ac93501f
Full Text :
https://doi.org/10.1016/s0959-8049(03)00931-6